Cargando…
Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
BACKGROUND: In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise tolerance. CASE PRESENTATION: A 38-year-old fem...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659015/ https://www.ncbi.nlm.nih.gov/pubmed/29073911 http://dx.doi.org/10.1186/s12890-017-0480-9 |
_version_ | 1783274098910035968 |
---|---|
author | Furukawa, Asuka Tamura, Yuichi Iwahori, Hiroya Goto, Masato Ohashi, Narutaka Okabe, Teruo Kawamura, Akio |
author_facet | Furukawa, Asuka Tamura, Yuichi Iwahori, Hiroya Goto, Masato Ohashi, Narutaka Okabe, Teruo Kawamura, Akio |
author_sort | Furukawa, Asuka |
collection | PubMed |
description | BACKGROUND: In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise tolerance. CASE PRESENTATION: A 38-year-old female with idiopathic PAH (IPAH) had received initial triple combination therapy (macitentan PO, tadalafil PO, and treprostinil SC) and achieved excellent improvement in hemodynamics. Afterwards, due to the development of side effects from subcutaneous administration, we replaced treprostinil therapy with oral selexipag, resulting in stable hemodynamic parameters and exercise capacities. CONCLUSIONS: We report the first case of successful replacement of treprostinil (20.1 ng/kg/min) with selexipag (1600 μg BID) as a component of triple combination therapy, which provides incentive to perform a larger, prospective exchange study. |
format | Online Article Text |
id | pubmed-5659015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56590152017-11-01 Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension Furukawa, Asuka Tamura, Yuichi Iwahori, Hiroya Goto, Masato Ohashi, Narutaka Okabe, Teruo Kawamura, Akio BMC Pulm Med Case Report BACKGROUND: In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise tolerance. CASE PRESENTATION: A 38-year-old female with idiopathic PAH (IPAH) had received initial triple combination therapy (macitentan PO, tadalafil PO, and treprostinil SC) and achieved excellent improvement in hemodynamics. Afterwards, due to the development of side effects from subcutaneous administration, we replaced treprostinil therapy with oral selexipag, resulting in stable hemodynamic parameters and exercise capacities. CONCLUSIONS: We report the first case of successful replacement of treprostinil (20.1 ng/kg/min) with selexipag (1600 μg BID) as a component of triple combination therapy, which provides incentive to perform a larger, prospective exchange study. BioMed Central 2017-10-26 /pmc/articles/PMC5659015/ /pubmed/29073911 http://dx.doi.org/10.1186/s12890-017-0480-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Furukawa, Asuka Tamura, Yuichi Iwahori, Hiroya Goto, Masato Ohashi, Narutaka Okabe, Teruo Kawamura, Akio Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension |
title | Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension |
title_full | Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension |
title_fullStr | Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension |
title_full_unstemmed | Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension |
title_short | Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension |
title_sort | successful transition from treprostinil to selexipag in patient with severe pulmonary arterial hypertension |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659015/ https://www.ncbi.nlm.nih.gov/pubmed/29073911 http://dx.doi.org/10.1186/s12890-017-0480-9 |
work_keys_str_mv | AT furukawaasuka successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension AT tamurayuichi successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension AT iwahorihiroya successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension AT gotomasato successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension AT ohashinarutaka successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension AT okabeteruo successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension AT kawamuraakio successfultransitionfromtreprostiniltoselexipaginpatientwithseverepulmonaryarterialhypertension |